Johnson & Johnson
Close on Nov 4, 2026Market cap $665.90BP/E 41.9Yield 1.86%
Johnson & Johnson Other Pulmonary Hypertension medicines by Year
Other Pulmonary Hypertension medicines — U.S. operational growth YoY (%) (%)
Johnson & Johnson Other Pulmonary Hypertension medicines: -27.0% in FY2025, down 68.8 pts from a year earlier.
Where the FY2025 figure comes from
“|| US | 54 | 75 | (27.0) | (27.0) | —”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Pulmonary Hypertension medicines — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | -27.0% | -68.8 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 41.8% | +70.4 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | -28.6% | +3.7 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | -32.3% | -28.6 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | -3.7% | +13.9 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | -17.6% | – | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Other Pulmonary Hypertension medicines (%), annual FY2020–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-other-ph-us-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?